Stocks of Evolus Inc. (EOLS) are poised to climb above their peers

Evolus Inc. (NASDAQ: EOLS) stock fell -0.18% on Monday to $11.03 against a previous-day closing price of $11.05. With 0.82 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.42 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $11.49 whereas the lowest price it dropped to was $10.99. The 52-week range on EOLS shows that it touched its highest point at $14.34 and its lowest point at $5.06 during that stretch. It currently has a 1-year price target of $16.56. Beta for the stock currently stands at 1.85.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EOLS was up-trending over the past week, with a rise of 27.51%, but this was up by 58.25% over a month. Three-month performance surged to 32.10% while six-month performance fell -12.74%. The stock gained 99.10% in the past year, while it has gained 46.87% so far this year. A look at the trailing 12-month EPS for EOLS yields -1.42 with Next year EPS estimates of -0.38. For the next quarter, that number is -0.16. This implies an EPS growth rate of 80.50% for this year and 65.00% for next year. EPS is expected to grow by 16.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -2.00%.

Float and Shares Shorts:

At present, 56.18 million EOLS shares are outstanding with a float of 37.62 million shares on hand for trading. On Oct 13, 2022, short shares totaled 2.69 million, which was 4.80% higher than short shares on Sep 14, 2022. In addition to Mr. David Moatazedi as the firm’s Pres, CEO & Director, Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. serves as its Chief Medical Officer and Head of R&D.

Institutional Ownership:

Through their ownership of 48.88% of EOLS’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 49.56% of EOLS, in contrast to 32.97% held by mutual funds. Shares owned by individuals account for 15.88%. As the largest shareholder in EOLS with 9.58% of the stake, Deerfield Management Co. LP holds 5,390,103 shares worth 5,390,103. A second-largest stockholder of EOLS, First Manhattan Co., holds 4,034,938 shares, controlling over 7.17% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in EOLS, holding 2,144,895 shares or 3.81% stake. With a 1.96% stake in EOLS, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,102,093 shares are owned by the mutual fund manager. The FCP Medical – BioHealth, which owns about 1.62% of EOLS stock, is the second-largest Mutual Fund holder. It holds 913,703 shares valued at 6.86 million. iShares Russell 2000 ETF holds 1.46% of the stake in EOLS, owning 818,187 shares worth 6.14 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EOLS since 9 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With EOLS analysts setting a high price target of $20.00 and a low target of $10.00, the average target price over the next 12 months is $16.56. Based on these targets, EOLS could surge 81.32% to reach the target high and fall by -9.34% to reach the target low. Reaching the average price target will result in a growth of 50.14% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. EOLS will report FY 2022 earnings on 03/01/2024. Analysts have provided yearly estimates in a range of -$0.83 being high and -$1.04 being low. For EOLS, this leads to a yearly average estimate of -$0.93. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Evolus Inc. surprised analysts by $0.03 when it reported -$0.28 EPS against a consensus estimate of -$0.31. The surprise factor in the prior quarter was -$0.06. Based on analyst estimates, the high estimate for the next quarter is -$0.07 and the low estimate is -$0.26. The average estimate for the next quarter is thus -$0.17.

Summary of Insider Activity:

Insiders traded EOLS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 17 while that of sell transactions has risen to 17 over the past year. The total number of shares bought during that period was 551,246 while 408,945 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *